A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity

Clinical Cancer Research

Volumn 17, Issue 11, 2011, Pages 3673-3685

  Gillies, Stephen D ^a,d   Lan, Yan ^a   Hettmann, Thore ^a,e   Brunkhorst, Beatrice ^a   Sun, Yaping ^a   Mueller, Stefan O ^b,c   Lo, Kin Ming ^a  

^a EMD Serono Research Institute   (United States)

^b Merck Serono GmbH   (Germany)

^c KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^d Provenance Biopharmaceuticals   (United States)

^e U3 Pharma AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EMD 521873; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2LT NHS76 FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; GENE MUTATION; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MACACA FASCICULARIS; MALE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN VARIANT; RECEPTOR SENSITIVITY; TOXICITY TESTING; TUMOR IMMUNITY; WILD TYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; IMMUNOGLOBULIN VARIABLE REGION; INTERLEUKIN-2; MACACA FASCICULARIS; MICE; MULTIPLE MYELOMA; MUTATION; NEUROBLASTOMA; PROTEIN ENGINEERING; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS;

EID: 79957917039     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2921     Document Type: Article

References (34)

1. Lee W, Lee J, Henderson C, Taylor HF, James R, Lee CE, et al. Highdose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
2. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci U S A 1999;96:3957-62. (Pubitemid 29169018)
3. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst 2003;95:741-9. (Pubitemid 36665502)
4. Shanafelt AB, Lin Y, Shanafelt MC, Forte CP, Dubois-Stringfellow N, Carter C, et al. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat Biotechnol 2000;18:1197-202.
5. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990;171:1509-26. (Pubitemid 20167547)
6. Davis CB, Gillies SD. Immunocytokines: amplification of anti-cancer immunity. Cancer Immunol Immunother 2003;52:297-308. (Pubitemid 36578024)
7. Gillies SD, Lan Y, Williams S, Carr F, Forman S, Raubitschek A, et al. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 2005;105:3972-8. (Pubitemid 40656145)
8. Sharifi J, Khawli LA, Hu P, King S, Epstein AL. Characterization of a phage display-derived human monoclonal antibody (NHS76) counter-part to chimeric TNT-1 directed against necrotic regions of solid tumors. Hybrid Hybridomics 2001;20:305-12. (Pubitemid 34756999)
9. Epstein AL, Khawli LA, Chen F-M, Hu P, Glasky MS, Taylor CR. Tumor necrosis imaging and treatment of solid tumors. In: Torchilin VP, editor. Handbook of Targeted Delivery of Imaging Agents. Boca Raton (FL): CRC Press; 1995.
10. Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherpy in patients with advanced lung cancer. J Clin Oncol 2005;23:1538-47.
11. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005;65:8059-64. (Pubitemid 41330564)
12. Gillies SD, Lan Y, Wesolowski JS, Qian X, Reisfeld RA, Holden S, et al. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J Immunol 1998;160:6195-203. (Pubitemid 28298086)
13. Gillies SD, Lo KM, Burger C, Lan Y, Dahl T, Wong WK. Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin Cancer Res 2002;8:210-6. (Pubitemid 34101480)
14. Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 1978;120:2027-32. (Pubitemid 8356952)
15. Hori T, Uchiyama T, Tsudo M, Umadome H, Ohno H, Fukuhara S, et al. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 1987;70:1069-72. (Pubitemid 18022384)
16. Farner NL, Voss SD, Leary TP, Gan J, Hakimi J, Evans G, et al. Distinction between gamma c detection and function in YT lymphoid cells and in the granulocyte-macrophage colony-stimulating factor-responsive human myeloid cell line, Tf-1. Blood 1995;86:4568-78.
17. Damjanovich S, Bene L, Matkó J, Alileche A, Goldman CK, Sharrow S, et al. Preassembly of interleukin 2 (IL-2) receptor subunits on resting kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: a fluorescence resonance energy transfer study. Proc Natl Acad Sci U S A 1997;94:13134-9.
18. Johnson DR, Hauser IA, Voll RE, Emmrich F. Arterial and venular endothelial cell costimulation of cytokine secretion by human T cell clones. J Leukoc Biol 1998;63:612-9. (Pubitemid 28193775)
19. Hartmann G. Technology evaluation: BAY-50-4798, Bayer. Curr Opin Mol Ther 2004;6:221-7.
20. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993;73:5-8. (Pubitemid 23115443)
21. Kabouridis PS, Tsoukas CD. Regulation of expression of interleukin 2 receptors upon triggering of the TCR-CD3 complex on human T lymphocytes. Immunol Invest 1990;19:385-401. (Pubitemid 20305604)
22. Gillies SD, Young D, Lo KM, Roberts S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug Chem 1993;4:230-5.
23. Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, et al. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother 2004;27:232-9. (Pubitemid 39118088)
24. Harada Y, Yahara I. Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals. Int Rev Exp Pathol 1993;34:37-55.
25. King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, et al. Phase 1 clinical trial of the immunocytokine EMD273063 in melanoma patients.J Clin Oncol 2004;22:4463-73.
26. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited.FASEB J 2007;22:659-61.
27. Vial T, Descotes J. Clinical toxicity of interleukin-2. Drug Saf 1992;7:417-33.
28. Waldmann TA. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunology Today 1993;14:264-70. (Pubitemid 23186988)
29. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-30. (Pubitemid 24091790)
30. Gorgani NN, Smith BA, Kono DH, Theofilopoulos AN. Histidine-rich glycoprotein binds to DNA and Fc gamma RI and potentiates the ingestion of apoptotic cells by macrophages. J Immunol 2002;169:4745-51. (Pubitemid 35217136)
31. Cheng FM, Hansen EB, Taylor CR, Epstein AL. Diffusion and binding of monoclonal antibody TNT-1 in multicellular tumor spheroids. J Natl Cancer Inst 1991;83:200-4.
32. Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 1991;353:858-61. (Pubitemid 21912642)
33. + regulatory T cell function. Eur J Immunol 2004;34:2480-8.
34. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704.